Tafamidis is SFDA-registered at an 80-90% tender discount, but fewer than 8 GCC centres can diagnose ATTR-CM.

Tafamidis (Vyndaqel/Vyndamax), which produced a 29.5% relative reduction in all-cause mortality in ATTR-ACT, is SFDA-registered since 2021 and available via specialist prescription at cardiology centres including KAMC, KFSH&RC, and AUH. Annual tafamidis tender pricing in KSA runs approximately SAR 70,000-90,000, versus a US WAC equivalent near SAR 850,000, an 80-90% discount reflecting GCC reference pricing to Portugal and Greece plus direct negotiating leverage. NPHC evaluation of tafamidis for ATTR-CM has not yet been formalised in KSA; access today runs on specialist prescription with case-by-case MOH approval. Vutrisiran for ATTR-PN carries a GCC registration timeline of 18 to 24 months behind its 2022 FDA approval.

The primary barrier to the GCC ATTR opportunity is diagnostic infrastructure, not drug registration or price. Tc-PYP scintigraphy, the non-invasive diagnostic standard for ATTR-CM, is available at fewer than 8 centres across all six GCC states, and most HFpEF patients are managed by general cardiologists without ATTR screening, leaving an estimated diagnosis rate below 5% of true prevalence. The GCC also carries its own genetic profile: hereditary ATTR variants beyond the globally common Val30Met include several Arabian Peninsula-specific mutations documented in Saudi, UAE, and Omani kindreds, with total ATTRv burden estimated at 500 to 1,000 patients regionwide.

Scintigraphy access, not tafamidis price or registration, gates the GCC ATTR-CM opportunity.

Five questions this report answers:

Q1 - What does 80-90% tender-discount pricing on tafamidis mean for a new entrant's GCC strategy?

Q2 - Where is Tc-PYP scintigraphy capacity concentrated across the six GCC states?

Q3 - How do GCC-specific ATTRv genetic variants change the hereditary-ATTR commercial opportunity?

Q4 - Why is the ATTR opportunity gated by diagnostic infrastructure rather than drug access?

Q5 - How does the NPHC case-by-case approval process work for tafamidis in ATTR-CM?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ATTRAmyloidosis #GCC #Tafamidis #Cardiology #RareDisease #MarketAccess

Live report page:  https://axlrx.ai/attr-amyloidosis/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/